Spyre Therapeutics Announces Public Stock Offering

Spyre Therapeutics ( (SYRE) ) has provided an announcement.

On October 13, 2025, Spyre Therapeutics entered into an underwriting agreement with several financial firms for the public offering of 14,864,865 shares of its common stock at $18.50 per share, raising approximately $316.2 million in gross proceeds. The funds will support the company’s ongoing research and development efforts, including Phase 3 readiness activities for its antibody programs, as well as general corporate purposes.

The most recent analyst rating on (SYRE) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Spyre Therapeutics stock, see the SYRE Stock Forecast page.

Spark’s Take on SYRE Stock

According to Spark, TipRanks’ AI Analyst, SYRE is a Neutral.

Spyre Therapeutics is facing significant financial challenges with consistent revenue and profitability issues. Its strong equity position is overshadowed by operational cash flow problems and persistent losses. Technically, the stock is under bearish pressure, and the valuation is complicated by a negative P/E ratio and lack of dividends. These factors combined result in a low overall stock score, reflecting the high-risk nature of investing in this biotechnology company.

To see Spark’s full report on SYRE stock, click here.

More about Spyre Therapeutics

Spyre Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing treatments for inflammatory bowel disease and rheumatic diseases. The company is advancing its antibody programs through preclinical studies, clinical trials, and manufacturing activities.

Average Trading Volume: 684,015

Technical Sentiment Signal: Sell

Current Market Cap: $1.14B

Learn more about SYRE stock on TipRanks’ Stock Analysis page.